2007
Diverse Contribution of Bone Marrow–Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation
Sahara M, Sata M, Morita T, Nakamura K, Hirata Y, Nagai R. Diverse Contribution of Bone Marrow–Derived Cells to Vascular Remodeling Associated With Pulmonary Arterial Hypertension and Arterial Neointimal Formation. Circulation 2007, 115: 509-517. PMID: 17242277, DOI: 10.1161/circulationaha.106.655837.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnimals, Genetically ModifiedArteriolesBone Marrow CellsBone Marrow TransplantationCapillariesCell DifferentiationDisease Models, AnimalFemoral ArteryGreen Fluorescent ProteinsHypertension, PulmonaryMaleMonocrotalinePneumonectomyPulmonary ArteryPulmonary EmbolismRatsRats, Sprague-DawleyThrombosisTunica IntimaVentricular Dysfunction, RightConceptsPulmonary arterial hypertensionArterial neointimal formationBM-derived cellsPulmonary arterial remodelingArterial hypertensionPulmonary arteriolesProtein-positive cellsSmooth muscle cellsGreen fluorescent protein-positive cellsArterial remodelingFemoral arteryBM cellsNeointimal formationBone marrowMonocrotaline-induced pulmonary arterial hypertensionRight ventricular systolic pressureMuscle cellsVascular Remodeling AssociatedVentricular systolic pressureGreen fluorescent protein (GFP) transgenic ratsSmooth muscle-like cellsSprague-Dawley ratsWire-injured femoral arteriesMuscle-like cellsPulmonary hypertension
2006
New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension
Sahara M, Takahashi T, Imai Y, Nakajima T, Yao A, Morita T, Hirata Y, Nagai R. New Insights in the Treatment Strategy for Pulmonary Arterial Hypertension. Cardiovascular Drugs And Therapy 2006, 20: 377-386. PMID: 17124557, DOI: 10.1007/s10557-006-0498-3.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAnticoagulantsAntihypertensive AgentsCalcium Channel BlockersDiureticsDrug Therapy, CombinationHumansHypertension, PulmonaryMaleMiddle AgedNicorandilNitric Oxide DonorsOxygen Inhalation TherapyPhosphodiesterase InhibitorsPiperazinesPurinesPyridazinesSildenafil CitrateSulfonesVasodilator AgentsConceptsPulmonary arterial hypertensionFunctional class IVArterial hypertensionNew York Heart Association functional class IVNYHA functional class IVPhosphodiesterase type 5 inhibitorsClass IVIntravenous prostacyclin therapyOral combination therapyRational pharmacological therapyFirst-line therapyPhosphodiesterase type 3 inhibitorPrimary pulmonary hypertensionEndothelin receptor antagonistsCurrent treatment optionsCalcium channel blockersLong-term efficacyType 5 inhibitorsNovel therapeutic approachesLong-term survivalProstacyclin therapyExercise tolerancePulmonary hypertensionMale patientsPharmacological therapy